Trump Administration Secures Major Drug Pricing Deals with Pharmaceutical Giants, Mandates US Manufacturing Expansion
核心洞察
The Trump Administration announced landmark agreements with Eli Lilly, Novo Nordisk, and Gilead Sciences that reduce prescription drug costs by up to 79% through Most Favored Nation pricing deals.
Ozempic and Wegovy prices will drop from over $1,000 monthly to $350, while future oral GLP-1 (搜索) drugs will launch at $150 per month, with Medicare covering anti-obesity medications for the first time.
The deals mandate historic US manufacturing investments totaling over $69 billion, including Eli Lilly's $27 billion expansion and Novo Nordisk's $10 billion commitment to domestic production.
The Trump Administration has announced sweeping pharmaceutical agreements that simultaneously slash prescription drug prices and mandate unprecedented domestic manufacturing investments, marking a fundamental shift in US drug policy. The deals with Eli Lilly, Novo Nordisk, and Gilead Sciences represent the largest coordinated effort to reduce medication costs while rebuilding America's pharmaceutical supply chain.
Historic Price Reductions for Diabetes and Obesity Medications
Through the federal TrumpRx direct-to-consumer platform, the administration secured dramatic price cuts on critical diabetes and obesity treatments. Novo Nordisk's Ozempic and Wegovy will see monthly costs plummet from $1,000 and $1,350 respectively to $350 per month—a reduction of more than two-thirds. Eli Lilly's Zepbound and orforglipron will be available at $346 per month once approved, while potential oral GLP-1 (搜索) drugs pending FDA approval will launch at just $150 per month.
The pricing reforms enable Medicare and Medicaid to cover anti-obesity medications for the first time, with Medicare capping patient copays at $50. This expansion addresses a critical public health need, as 40% of US adults are obese, driving increases in type 2 diabetes, cardiovascular disease, hypertension, and stroke.
Unprecedented Manufacturing Commitments
The agreements tie these price reductions to massive domestic production investments. Eli Lilly announced at least $27 billion in new US manufacturing investments as part of a broader post-2020 expansion exceeding $50 billion, constituting the largest pharmaceutical manufacturing buildout in US history. Three of Eli Lilly's four new facilities will produce active pharmaceutical ingredients such as tirzepatide, while the fourth will focus on injectable medicines.
Novo Nordisk committed an additional $10 billion to strengthen its US footprint, including domestic, end-to-end production of a potential Wegovy tablet. The company's expanded North Carolina facilities are already supporting oral semaglutide manufacturing, addressing supply disruptions experienced during recent shortages.
Gilead's Comprehensive Agreement
Gilead Sciences entered a three-year agreement implementing a new pricing strategy that ensures the US no longer bears a disproportionate share of global healthcare costs. The deal includes discounts on existing medicines within the US Medicaid program for HIV (搜索), hepatitis C, hepatitis B, and COVID-19 (搜索) treatments, with pricing comparable to other developed nations.
"This agreement reflects a foundational commitment to both affordability and future innovation," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences. The company will launch a Direct-to-Patient Program making its hepatitis C treatment Epclusa available at discounted cash prices through TrumpRx.gov.
Gilead also announced a $32 billion investment in US-based manufacturing, R&D, and infrastructure over five years, projected to generate $43 billion in national economic value and create more than 3,000 direct and indirect jobs.
Fertility Treatment Cost Reductions
In a separate initiative, the administration secured an agreement with EMD Serono delivering 42-79% reductions in drug costs for typical IVF cycles. The company's full fertility portfolio will join TrumpRx starting in 2026, with EMD Serono receiving exemption from upcoming US pharmaceutical tariffs conditional on expanded domestic manufacturing and research investment.
Strategic Industrial Transformation
These agreements represent more than traditional price controls, constituting a deliberate industrial transformation positioning the US as both anchor customer and primary manufacturing platform for next-generation therapies. The strategy moves beyond short-term price regulations to long-term national health and industrial revitalization, ensuring affordable, innovative medicines are produced domestically.
The coordinated approach addresses both immediate affordability concerns and long-term supply chain security, with companies maintaining discounts across their pipelines as they scale up US manufacturing. Together, these commitments support the shift towards making the US both a manufacturing hub and the global price-setting market for advanced metabolic therapies.